Could it be that there will be "a new PBT2 company" and the old ATH?
It has been evident that Stamler and Kempler are only interested in neurodegeneration and almost not at all in antibiotics. Perhaps the Fund could invest in the new firm and ATH would be the majority owner in the company with its license and give us, ATH investors part of these shares of the new company..
The new "PBT2 company" would be mostly a worldwide marketing company and it will need totally different management than a company developing new drugs for neurodegenerative diseases. Very difficult combination, if PBT2 will remain in ATH.
This long wait and "no news" policy both on the side of ATH and the Fund is perhaps best explained with this kind of deal, IMO.
Could it be that there will be "a new PBT2 company" and the old...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |